Integrating CTLA-4 Genetics and Soluble Isoforms for the Stratification of HCV-Related Hepatocellular Carcinoma Risk and Aggressiveness
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211067 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marwa Hassan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department, Theodor Bilharz Research Institute, Giza 12411, Egypt. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, CTLA-4 Antigen, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Host genetic factors influencing immune regulation are believed to modulate susceptibility to hepatitis C virus (HCV) and related hepatocellular carcinoma (HCC). This study aimed to investigate the association of Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) genetic variants with HCV-related HCC risk, soluble CTLA-4 (sCTLA-4) levels, and disease severity. 225 age- and sex-matched participants (75 controls, 75 HCV, and 75 HCV-HCC) were enrolled. TaqMan allelic discrimination assays were used for genotyping three CTLA-4 SNPs, and sCTLA-4 was quantified by ELISA. Our results demonstrated that the rs231726 TT genotype and T-allele were significantly associated with HCC. The rs11571317 CC genotype and C-allele, alongside the rs13384548 GG genotype and G-allele, conferred increased risk for both HCV and HCC. Clinically, these high-risk genotypes correlated with worse liver function (Child–Pugh C), higher MELD/Na scores, and larger tumors. Moreover, sCTLA-4 levels showed a stepwise elevation from controls to HCV to HCC patients, peaking in carriers of the rs231726 TT and rs13384548 GG genotypes. In conclusion, this study identifies rs231726, rs11571317, and rs13384548 as robust genetic markers for HCV-related HCC susceptibility and cancer aggressiveness. Our findings provide novel evidence of their role in immune evasion through sCTLA-4 upregulation, offering new perspectives into genotype-based risk stratification and tailored immunotherapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Department, Theodor Bilharz Research Institute, Giza 12411, Egypt.
- Pharmacology Department, Theodor Bilharz Research Institute, Giza 12411, Egypt.
- Biochemistry Department, School of Pharmacy, NewGiza University, Giza 12577, Egypt.
- Pharmacy Practice Department, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.
- Hepatogastoenterology Department, Theodor Bilharz Research Institute, Giza 12411, Egypt.
- University Hospital Rostock, Ernst-Heydemann-Straße 6, 18057 Rostock, Germany.
ORCID-Profile: Marwa Hassan, Walaa H El-Maadawy, Sally A Fahim
Zitieren
APA
Hassan, M., El-Maadawy, W. H., Fahim, S. A., Youssef, S. M., Badran, O. M., & Balata, M. (2025). Integrating CTLA-4 Genetics and Soluble Isoforms for the Stratification of HCV-Related Hepatocellular Carcinoma Risk and Aggressiveness. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211067
Vancouver
Hassan M, El-Maadawy WH, Fahim SA, Youssef SM, Badran OM, Balata M. Integrating CTLA-4 Genetics and Soluble Isoforms for the Stratification of HCV-Related Hepatocellular Carcinoma Risk and Aggressiveness. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211067
BibTeX
@article{Hassan2025,
author = {Hassan, Marwa and El-Maadawy, Walaa H and Fahim, Sally A and Youssef, Sherihan M and Badran, Omaima Mostafa and Balata, Mahmoud},
title = {Integrating CTLA-4 Genetics and Soluble Isoforms for the Stratification of HCV-Related Hepatocellular Carcinoma Risk and Aggressiveness},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211067}
}
EUVIMED